Status:
COMPLETED
To Investigate the Role of Gut Microbiome in ADT Related Metabolic Changes in Prostate Cancer Patients
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Prostate Cancer
Eligibility:
MALE
45+ years
Brief Summary
Prostate cancer is the second most common cancer in male cancer globally and ranked third in Hong Kong. While androgen deprivation therapy (ADT) is the backbone treatment for advanced prostate cancer,...
Detailed Description
It is a prospective longitudinal observational human study. Fifty prostate cancer patients planned for ADT will be recruited. Fecal sample will be collected before initiation of ADT, and then at 3 and...
Eligibility Criteria
Inclusion
- Male subject with age 45 or above
- Histological diagnosis of prostate cancer (acinar type)
- Clinically decided for androgen deprivation therapy (ADT) as treatment for prostate cancer
Exclusion
- History of diabetes
- Patients that have other active treatment for prostate cancer or other cancers (except ADT)
- Patients received treatment, either surgical or medical, that could lead to decrease in serum testosterone prior to commencement of ADT
- Patients will be started on other treatments, including chemotherapy, new generation of androgen-receptor targeted agents, radiotherapy etc, within 6 months of the commencement of ADT.
- Subject with recent antibiotics usage within 3 months.
Key Trial Info
Start Date :
January 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 26 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04687709
Start Date
January 14 2021
End Date
September 26 2023
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, Hong Kong